138 related articles for article (PubMed ID: 2614669)
1. [Studies on the relationship between therapeutic schedule and antitumor effect of etoposide and cytosine arabinoside in murine L1210 leukemia].
Ooi K; Ohkubo T; Kawasaki H; Sakurai M
Yakugaku Zasshi; 1989 Nov; 109(11):865-8. PubMed ID: 2614669
[TBL] [Abstract][Full Text] [Related]
2. [The mechanism of synergistic interaction between etoposide and cytarabine].
Ooi K
Yakugaku Zasshi; 2002 Jul; 122(7):471-80. PubMed ID: 12136643
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent antitumor effect of VP-16 and 1-beta-D-arabinofuranosylcytosine in L1210 ascites tumor.
Ohkubo T; Higashigawa M; Kawasaki H; Kamiya H; Sakurai M; Kagawa Y; Kakito E; Sumida K; Ooi K
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1823-8. PubMed ID: 3220079
[TBL] [Abstract][Full Text] [Related]
4. Enhanced incorporation of 1-beta-D-arabinofuranosylcytosine by pretreatment with etoposide.
Ooi K; Ohkubo T; Kuwabara H; Higashigawa M; Kawasaki H; Kakitoh H; Kagawa Y; Inagaki S; Sumida K; Sakurai M
Cancer Invest; 1993; 11(4):388-92. PubMed ID: 8324643
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between etoposide and 1-beta-D-arabinofuranosylcytosine.
Ohkubo T; Hori H; Higashigawa M; Kawasaki H; Kamiya H; Sakurai M; Kagawa Y; Kakito E; Sumida K; Ooi K
Adv Exp Med Biol; 1989; 253B():355-62. PubMed ID: 2610123
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
Grem JL; Plowman J; Rubinstein L; Hawkins MJ; Harrison SD
Leuk Res; 1991; 15(4):229-36. PubMed ID: 2030604
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
8. Timing- and sequence-dependent synergism between etoposide and methotrexate or etoposide, methotrexate and 5-fluorouracil in advanced leukemia L1210.
Osswald H; Herrmann R; Youssef M
Cancer Lett; 1985 Dec; 29(3):277-82. PubMed ID: 4075296
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
Hashida M; Kojima T; Muranishi S; Sezaki H
Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.
Momparler RL; Momparler LF
Cancer Chemother Pharmacol; 1989; 25(1):51-4. PubMed ID: 2480188
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells.
Roberts D; Peck C; Hilliard S; Wingo W
Cancer Res; 1979 Oct; 39(10):4048-54. PubMed ID: 476642
[TBL] [Abstract][Full Text] [Related]
12. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.
Avery TL; Roberts D
Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345
[No Abstract] [Full Text] [Related]
13. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
14. [Etoposide-induced deoxyribonucleic acid (DNA) damage and its effects on nucleotide pools in murine leukemia L1210 cells].
Ooi K; Ohkubo T; Kawasaki H; Sakurai M
Yakugaku Zasshi; 1990 Sep; 110(9):673-7. PubMed ID: 2262879
[TBL] [Abstract][Full Text] [Related]
15. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
Koyama S; Itou S; Shibata A
Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
[TBL] [Abstract][Full Text] [Related]
16. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
Rubas W; Supersaxo A; Weder HG; Hartmann HR; Hengartner H; Schott H; Schwendener R
Int J Cancer; 1986 Jan; 37(1):149-54. PubMed ID: 3941019
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
[TBL] [Abstract][Full Text] [Related]
19. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
[No Abstract] [Full Text] [Related]
20. Response of lymphoid leukemia L1210 in mice to implantable sustained release cytosine arabinoside capsules.
Fu JC; Khwaja T; Moyer DL; Cummings L; Varvan J; Elshire D
J Surg Oncol; 1978; 10(1):1-7. PubMed ID: 628213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
